SSJR is pleased to report it has successfully secured a dismissal of a Hatch-Waxman patent infringement case against its client Sandoz. The case was initiated when GlaxoSmithKline (“GSK”) asserted that Sandoz’s generic version of GSK’s anti-nausea drug Zofran® (Ondansetron) infringed U.S. Patent No. 5,344,658. Through its work SSJR was successful in convincing GSK to dismiss its infringement case against Sandoz. The dismissal of the case with prejudice from the U.S. District Court of New Jersey clears the way for Sandoz to sell its generic version of Zofran® once final FDA approval is granted.